NCT02581787View on ClinicalTrials.gov

SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

March 2, 2023

Study Completion Date

March 2, 2023

Conditions
Stage IA Non-Small Cell Lung CarcinomaStage IB Non-Small Cell Lung Carcinoma
Interventions
BIOLOGICAL

Fresolimumab

Given IV

RADIATION

Stereotactic Body Radiation Therapy

Undergo SABR

Trial Locations (1)

94304

Stanford University, School of Medicine, Palo Alto

Sponsors

Collaborators (1)

Varian Medical Systems
All Listed Sponsors
collaborator

Varian Medical Systems

INDUSTRY

lead

Maximilian Diehn

OTHER